Self-Assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-Positive Gastric Cancer

Functionalized DNA Nanomaterials Targeting Toll‐Like Receptor 4 Prevent Bisphosphonate‐Related Osteonecrosis of the Jaw via Regulating Mitochondrial Homeostasis in Macrophages

(2023) Tao Zhang et al.   ADVANCED FUNCTIONAL MATERIALS

A dynamic DNA tetrahedron framework for active targeting

(2023) Taoran Tian et al.   Nature Protocols

Typhaneoside-Tetrahedral Framework Nucleic Acids System: Mitochondrial Recovery and Antioxidation for Acute Kidney Injury treatment

(2023) Ran Yan et al.   ACS Nano

Effects of Puerarin‐Loaded Tetrahedral Framework Nucleic Acids on Osteonecrosis of the Femoral Head

(2023) Yuxuan Zhao et al.   Small

Amelioration of Osteoarthritis via Tetrahedral Framework Nucleic Acids Delivering Microrna‐124 for Cartilage Regeneration

(2023) Sirong Shi et al.   ADVANCED FUNCTIONAL MATERIALS

A Transdermal Drug Delivery System Based on Nucleic Acid Nanomaterials for Skin Photodamage Treatment

(2023) Yu Xie et al.   ADVANCED FUNCTIONAL MATERIALS

Facilitating In Situ Tumor Imaging with a Tetrahedral DNA Framework‐Enhanced Hybridization Chain Reaction Probe

(2022) Bowen Zhang et al.   ADVANCED FUNCTIONAL MATERIALS

Biomimetic Nanoerythrosome‐Coated Aptamer–DNA Tetrahedron/Maytansine Conjugates: pH‐Responsive and Targeted Cytotoxicity for HER2‐Positive Breast Cancer

(2022) Wenjuan Ma et al.   ADVANCED MATERIALS

The development of peptide-drug conjugates (PDCs) strategies for paclitaxel

(2022) Longkun Wang et al.   Expert Opinion on Drug Delivery

Aptamers Entirely Built from Therapeutic Nucleoside Analogues for Targeted Cancer Therapy

(2022) Lijuan Zhu et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Tetrahedral Framework Nucleic Acids Can Alleviate Taurocholate-Induced Severe Acute Pancreatitis and Its Subsequent Multiorgan Injury in Mice

(2022) Yun Wang et al.   NANO LETTERS

Site-Specific Chemoenzymatic Conjugation of High-Affinity M6P Glycan Ligands to Antibodies for Targeted Protein Degradation

(2022) Xiao Zhang et al.   ACS Chemical Biology

Inhibition of the endosomal recycling pathway downregulates HER2 activation and overcomes resistance to tyrosine kinase inhibitors in HER2-positive breast cancer

(2022) Anurag Mishra et al.   CANCER LETTERS

Antiepilepticus Effects of Tetrahedral Framework Nucleic Acid via Inhibition of Gliosis-Induced Downregulation of Glutamine Synthetase and Increased AMPAR Internalization in the Postsynaptic Membrane

(2022) Jianwei Zhu et al.   NANO LETTERS

Semiconducting Polymer Nanoparticles with Surface‐Mimicking Protein Secondary Structure as Lysosome‐Targeting Chimaeras for Self‐Synergistic Cancer Immunotherapy

(2022) Ji Qi et al.   ADVANCED MATERIALS

Myelosuppression Alleviation and Hematopoietic Regeneration by Tetrahedral‐Framework Nucleic‐Acid Nanostructures Functionalized with Osteogenic Growth Peptide

(2022) Tianxu Zhang et al.   Advanced Science

Current treatment and recent progress in gastric cancer

(2021) Smita S. Joshi et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Aptamer-Based Detection of Circulating Targets for Precision Medicine

(2021) Lingling Wu et al.   CHEMICAL REVIEWS

Enhancing anti‐PD‐1 immunotherapy by nanomicelles self‐assembled from aptamer‐multivalent‐drug conjugates

(2021) Zhongmin Geng et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

(2021) Salvatore Siena et al.   LANCET ONCOLOGY

Tetrahedral Framework Nucleic Acids Induce Immune Tolerance and Prevent the Onset of Type 1 Diabetes

(2021) Shaojingya Gao et al.   NANO LETTERS

LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation

(2021) Green Ahn et al.   Nature Chemical Biology

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity

(2021) Ariella B. Hanker et al.   CANCER CELL

Melatonin potentiates the cytotoxic effect of Neratinib in HER2+ breast cancer through promoting endocytosis and lysosomal degradation of HER2

(2021) Zundong Liu et al.   ONCOGENE

Functionalizing Framework Nucleic‐Acid‐Based Nanostructures for Biomedical Application

(2021) Tao Zhang et al.   ADVANCED MATERIALS

Structures of the HER2–HER3–NRG1β complex reveal a dynamic dimer interface

(2021) Devan Diwanji et al.   NATURE

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

(2020) Shanu Modi et al.   JOURNAL OF CLINICAL ONCOLOGY

Nucleic Acid Aptamers for Molecular Diagnostics and Therapeutics: Advances and Perspectives

(2020) Weihong Tan et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

(2020) Kohei Shitara et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor microenvironment (TME)-activatable circular aptamer-PEG as an effective hierarchical-targeting molecular medicine for photodynamic therapy

(2020) Yu Yang et al.   BIOMATERIALS

Gastric cancer

(2020) Elizabeth C Smyth et al.   LANCET

Aptamer-Peptide Conjugates as Targeted Chemosensitizers for Breast Cancer Treatment

(2020) Yan Tan et al.   ACS Applied Materials & Interfaces

Accelerating Post-SELEX Aptamer Engineering Using Exonuclease Digestion

(2020) Juan Canoura et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study

(2020) Jae Ho Jeong et al.   EUROPEAN JOURNAL OF CANCER

Breast Cancer Treatment

(2019) Adrienne G. Waks et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

(2019) Kenji Tamura et al.   LANCET ONCOLOGY

An Intelligent DNA Nanorobot with in Vitro Enhanced Protein Lysosomal Degradation of HER2

(2019) Wenjuan Ma et al.   NANO LETTERS

Redox-Switchable Binding Properties of the ATP–Aptamer

(2019) Yonatan Biniuri et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Antibody–drug conjugates for cancer

(2019) Cindy H Chau et al.   LANCET

Polymeric Engineering of Aptamer–Drug Conjugates for Targeted Cancer Therapy

(2019) Zhengyu Deng et al.   BIOCONJUGATE CHEMISTRY

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

(2019) Shanu Modi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aptamer-based targeted therapy

(2018) Guizhi Zhu et al.   ADVANCED DRUG DELIVERY REVIEWS

A basic insight into aptamer-drug conjugates (ApDCs)

(2018) Wenjing Xuan et al.   BIOMATERIALS

Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer

(2018) De-Shen Wang et al.   GUT

Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes

(2018) Meghdad Abdollahpour-Alitappeh et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Breast cancer

(2017) Nadia Harbeck et al.   LANCET

Enhanced Human Epidermal Growth Factor Receptor 2 Degradation in Breast Cancer Cells by Lysosome-Targeting Gold Nanoconstructs

(2015) Hyojin Lee et al.   ACS Nano

The catalytic region and PEST domain of PTPN18 distinctly regulate the HER2 phosphorylation and ubiquitination barcodes

(2014) Hong-Mei Wang et al.   CELL RESEARCH

Automated Modular Synthesis of Aptamer–Drug Conjugates for Targeted Drug Delivery

(2014) RuoWen Wang et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer

(2014) Xiang-hua Liu et al.   Molecular Cancer